BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 33406218)

  • 1. A comprehensive drug repurposing study for COVID19 treatment: novel putative dihydroorotate dehydrogenase inhibitors show association to serotonin-dopamine receptors.
    Berber B; Doluca O
    Brief Bioinform; 2021 Mar; 22(2):1023-1037. PubMed ID: 33406218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro.
    Hahn F; Wangen C; Häge S; Peter AS; Dobler G; Hurst B; Julander J; Fuchs J; Ruzsics Z; Überla K; Jäck HM; Ptak R; Muehler A; Gröppel M; Vitt D; Peelen E; Kohlhof H; Marschall M
    Viruses; 2020 Dec; 12(12):. PubMed ID: 33291455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors "leflunomide" and "teriflunomide" in Covid-19: A narrative review.
    Kaur H; Sarma P; Bhattacharyya A; Sharma S; Chhimpa N; Prajapat M; Prakash A; Kumar S; Singh A; Singh R; Avti P; Thota P; Medhi B
    Eur J Pharmacol; 2021 Sep; 906():174233. PubMed ID: 34111397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines.
    Luban J; Sattler RA; Mühlberger E; Graci JD; Cao L; Weetall M; Trotta C; Colacino JM; Bavari S; Strambio-De-Castillia C; Suder EL; Wang Y; Soloveva V; Cintron-Lue K; Naryshkin NA; Pykett M; Welch EM; O'Keefe K; Kong R; Goodwin E; Jacobson A; Paessler S; Peltz SW
    Virus Res; 2021 Jan; 292():198246. PubMed ID: 33249060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Dihydroorotate Dehydrogenase Inhibitors with Potent Interferon-Independent Antiviral Activity against Mammarenaviruses In Vitro.
    Kim YJ; Cubitt B; Cai Y; Kuhn JH; Vitt D; Kohlhof H; de la Torre JC
    Viruses; 2020 Jul; 12(8):. PubMed ID: 32751087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors.
    Vyas VK; Ghate M
    Mini Rev Med Chem; 2011 Oct; 11(12):1039-55. PubMed ID: 21861807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective deploying of a novel DHODH inhibitor against herpes simplex type 1 and type 2 replication.
    Luganini A; Sibille G; Mognetti B; Sainas S; Pippione AC; Giorgis M; Boschi D; Lolli ML; Gribaudo G
    Antiviral Res; 2021 May; 189():105057. PubMed ID: 33716051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA approved drugs with antiviral activity against SARS-CoV-2: From structure-based repurposing to host-specific mechanisms.
    Ahmed MS; Farag AB; Boys IN; Wang P; Menendez-Montes I; Nguyen NUN; Eitson JL; Ohlson MB; Fan W; McDougal MB; Mar K; Thet S; Ortiz F; Kim SY; Solmonson A; Williams NS; Lemoff A; DeBerardinis RJ; Schoggins JW; Sadek HA
    Biomed Pharmacother; 2023 Jun; 162():114614. PubMed ID: 37068330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of drug candidates for broad-spectrum antiviral therapy targeting cellular pyrimidine biosynthesis.
    Marschall M; Niemann I; Kosulin K; Bootz A; Wagner S; Dobner T; Herz T; Kramer B; Leban J; Vitt D; Stamminger T; Hutterer C; Strobl S
    Antiviral Res; 2013 Dec; 100(3):640-8. PubMed ID: 24149002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An in silico Workflow that Yields Experimentally Comparable Inhibitors for Human Dihydroorotate Dehydrogenase.
    M S; B P; Swaminathan P
    Curr Comput Aided Drug Des; 2020; 16(3):340-350. PubMed ID: 31132976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dihydroorotate dehydrogenase (DHODH) inhibitors affect ATP depletion, endogenous ROS and mediate S-phase arrest in breast cancer cells.
    Mohamad Fairus AK; Choudhary B; Hosahalli S; Kavitha N; Shatrah O
    Biochimie; 2017 Apr; 135():154-163. PubMed ID: 28196676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brequinar and dipyridamole in combination exhibits synergistic antiviral activity against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19.
    Demarest JF; Kienle M; Boytz R; Ayres M; Kim EJ; Patten JJ; Chung D; Gandhi V; Davey RA; Sykes DB; Shohdy N; Pottage JC; Kumar VS
    Antiviral Res; 2022 Oct; 206():105403. PubMed ID: 36041646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2.
    Xiong R; Zhang L; Li S; Sun Y; Ding M; Wang Y; Zhao Y; Wu Y; Shang W; Jiang X; Shan J; Shen Z; Tong Y; Xu L; Chen Y; Liu Y; Zou G; Lavillete D; Zhao Z; Wang R; Zhu L; Xiao G; Lan K; Li H; Xu K
    Protein Cell; 2020 Oct; 11(10):723-739. PubMed ID: 32754890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19.
    Talluri S
    Comb Chem High Throughput Screen; 2021; 24(5):716-728. PubMed ID: 32798373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
    Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
    Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Dihydroorotate Dehydrogenase Inhibitors Using the Cell Painting Assay.
    Schölermann B; Bonowski J; Grigalunas M; Burhop A; Xie Y; Hoock JGF; Liu J; Dow M; Nelson A; Nowak C; Pahl A; Sievers S; Ziegler S
    Chembiochem; 2022 Nov; 23(22):e202200475. PubMed ID: 36134475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Original 2-(3-Alkoxy-1H-pyrazol-1-yl)azines Inhibitors of Human Dihydroorotate Dehydrogenase (DHODH).
    Lucas-Hourani M; Munier-Lehmann H; El Mazouni F; Malmquist NA; Harpon J; Coutant EP; Guillou S; Helynck O; Noel A; Scherf A; Phillips MA; Tangy F; Vidalain PO; Janin YL
    J Med Chem; 2015 Jul; 58(14):5579-98. PubMed ID: 26079043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigating dihydroorotate dehydrogenase inhibitor mediated mitochondrial dysfunction in hepatic in vitro models.
    Jones SW; Penman SL; French NS; Park BK; Chadwick AE
    Toxicol In Vitro; 2021 Apr; 72():105096. PubMed ID: 33460737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional expression of human dihydroorotate dehydrogenase (DHODH) in pyr4 mutants of ustilago maydis allows target validation of DHODH inhibitors in vivo.
    Zameitat E; Freymark G; Dietz CD; Löffler M; Bölker M
    Appl Environ Microbiol; 2007 May; 73(10):3371-9. PubMed ID: 17369345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel series of human dihydroorotate dehydrogenase inhibitors discovered by in vitro screening: inhibition activity and crystallographic binding mode.
    Zeng T; Zuo Z; Luo Y; Zhao Y; Yu Y; Chen Q
    FEBS Open Bio; 2019 Aug; 9(8):1348-1354. PubMed ID: 31087527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.